Travere Therapeutics Inc. (TVTX)
NASDAQ: TVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
TVTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.04B
- Forward P/E
- 9.48
- EPS (TTM)
- -$0.74
- Dividend yield
- None
- 52-week range
- 22.59 – 68.73
- Day range
- 53.28 – 56.55
- Volume / Avg
- 3.42M / 1.55M
- Beta
- —
- Shares outstanding
- 94.26M
- Next earnings
- Oct 29, 2026
52-week range
TVTX stock today
On Oct 7, TVTX ended the session at $53.44, shedding $2.54 (4.54%), versus the S&P 500's 0.22% decline. Volume was 2.2x the average at 3.42M shares, a sign of unusually heavy trading. At this level, TVTX sits in the middle of its 52-week range of $22.59 to $68.73: 22.2% below the high, set on Sep 11, 2026 and 136.6% above the low.
TVTX is up 39.9% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 109.6%. Travere Therapeutics has posted a net loss over the last twelve months (EPS of -$0.74), so its P/E ratio is not meaningful. Travere Therapeutics's next earnings report is expected on Oct 29, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Travere Therapeutics
Company profileTravere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Eric M. Dube Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 497
- Website
- travere.com
Financial highlights
Full financialsIn fiscal 2025, Travere Therapeutics generated $490.7 million in revenue, up 110.5% from fiscal 2024, its 3rd consecutive year of revenue growth. Travere Therapeutics reported a net loss of $25.5 million, compared with a loss of $321.5 million a year earlier. Gross margin was 97.9% (up from 96.7%) and operating margin -12.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $490.73M | $233.18M | $145.24M | $109.46M | $131.84M |
| Growth | +110.45% | +60.55% | +32.69% | -16.97% | -33.52% |
| Net income | $-25.55M | $-321.55M | $-111.40M | $-278.48M | $-180.09M |
| EPS (diluted) | $-0.29 | $-4.08 | $-1.50 | $-4.37 | $-3.01 |
Analyst forecast
ForecastConsensus (15 analysts)
strong_buy
Avg. price target
$75.21+40.74%
- Strong buy 2
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $0.05
- Last reported (Q2 2026)
- Aug 4, 2026
- EPS actual vs est.
- $-0.37 vs —
Travere Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GRFSGrifols S.A. ADR | 7.50 | -0.27% | $5.10B | vs TVTX |
| ERASErasca Inc. | 14.12 | -1.26% | $4.94B | vs TVTX |
| COGTCogent Biosciences Inc. | 30.14 | -0.79% | $5.23B | vs TVTX |
| MIRMMirum Pharmaceuticals Inc. | 80.64 | +1.75% | $5.24B | vs TVTX |
| PTCTPTC Therapeutics Inc. | 63.23 | -0.74% | $5.28B | vs TVTX |
| MANEVeradermics Incorporated | 110.95 | +1.83% | $4.64B | vs TVTX |
| EWTXEdgewise Therapeutics Inc. | 39.57 | -1.12% | $4.30B | vs TVTX |
| INDVIndivior Pharmaceuticals Inc. | 36.13 | +0.64% | $4.26B | vs TVTX |
Indexes, lists and sector
Travere Therapeutics stock FAQ
What is Travere Therapeutics's stock price today?
TVTX last traded at $53.44 as of Oct 7, 4:00 PM EDT, down 4.54% on the day. Prices are delayed at least 15 minutes.
When is Travere Therapeutics's next earnings date?
Travere Therapeutics is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $0.05.
Who is Travere Therapeutics's CEO?
Dr. Eric M. Dube Ph.D. is the chief executive officer of Travere Therapeutics Inc., which has about 497 employees.
What is the TVTX 52-week high?
The 52-week high for TVTX is $68.73 and the 52-week low is $22.59. The stock is currently 22.2% below its high.